|
|
Volumn 13, Issue 8, 2002, Pages 1259-1263
|
|
Neovastat (Æ-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels
a
|
|
Author keywords
941; Angiogenesis; Anti angiogenic agent; Clinical trial; Neovastat; Renal cell carcinoma
|
|
Indexed keywords
AE 941;
ANGIOGENESIS INHIBITOR;
SHARK CARTILAGE EXTRACT AE 941;
TISSUE EXTRACT;
ADULT;
ADVANCED CANCER;
AGED;
ANOREXIA;
ARTICLE;
CANCER DIAGNOSIS;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG INFORMATION;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
EDEMA;
ERYTHEMA;
FEMALE;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
HYPOGLYCEMIA;
KIDNEY CARCINOMA;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
NAUSEA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
SOLID TUMOR;
SURVIVAL TIME;
TASTE DISORDER;
TUMOR VASCULARIZATION;
ANIMAL;
CARTILAGE;
CHEMISTRY;
COMPARATIVE STUDY;
KIDNEY TUMOR;
MIDDLE AGED;
PATHOLOGY;
SHARK;
SURVIVAL RATE;
VASCULARIZATION;
ADULT;
AGED;
ANGIOGENESIS INHIBITORS;
ANIMALS;
CARCINOMA, RENAL CELL;
CARTILAGE;
FEMALE;
HUMANS;
KIDNEY NEOPLASMS;
MALE;
MIDDLE AGED;
SHARKS;
SURVIVAL RATE;
TISSUE EXTRACTS;
|
|
EID: 0036668668
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdf195 Document Type: Article |
|
Times cited : (102)
|
|
References (21)
|
